Biologics/Update·FDA Vaccines, Blood & Biologics

OTP Events, Meetings, and Workshops

MediumPublished May 1, 2026· AI-analyzed May 4, 2026View original FDA source

AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.

What happened

The FDA's Office of Therapeutic Products (OTP) has updated or maintained its central directory for public events, meetings, and workshops. This resource serves as the primary notification hub for upcoming agency interactions regarding therapeutic biologics.

Who it affects

Manufacturers of cell and gene therapies, tissue-engineered products, and other advanced biologics regulated by OTP, as well as clinical researchers and regulatory professionals.

Why it matters

Direct engagement with OTP through these events often provides insight into the agency's current thinking on emerging technologies and regulatory science. Participation allows industry stakeholders to align development programs with evolving expectations and may signal upcoming shifts in administrative or technical focus areas.

Practical takeaway

Regulatory and development teams should monitor the Office of Therapeutic Products (OTP) calendar regularly to identify relevant public workshops or town halls. Stakeholders may consider preparing technical questions or position papers in anticipation of upcoming agency engagement opportunities.

FDA source material

Office of Therapeutic Products Events, Meetings, and Workshops

Open in openFDA / FDA.gov

AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.

OTP Events, Meetings, and Workshops

More from Biologics